Cencora, Inc. (NYSE:COR) Receives $373.25 Average Target Price from Analysts

Shares of Cencora, Inc. (NYSE:COR) have earned a consensus rating of “Moderate Buy” from the thirteen brokerages that are currently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $373.25.

A number of research analysts have issued reports on COR shares. UBS Group boosted their target price on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Robert W. Baird set a $392.00 price objective on Cencora in a research report on Tuesday, December 16th. Wells Fargo & Company raised their target price on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Finally, JPMorgan Chase & Co. lifted their target price on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th.

Insider Buying and Selling

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $343.45, for a total transaction of $1,750,221.20. Following the completion of the transaction, the chief executive officer owned 68,059 shares of the company’s stock, valued at $23,374,863.55. This trade represents a 6.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 20,317 shares of company stock valued at $7,009,260 over the last 90 days. 10.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cencora

A number of institutional investors and hedge funds have recently added to or reduced their stakes in COR. Baader Bank Aktiengesellschaft lifted its position in shares of Cencora by 318.5% during the second quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock worth $1,300,000 after purchasing an additional 3,300 shares in the last quarter. Voleon Capital Management LP bought a new position in Cencora in the 1st quarter worth approximately $3,111,000. Focus Partners Wealth lifted its holdings in Cencora by 25.8% during the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock worth $1,589,000 after buying an additional 1,171 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Cencora by 947.5% during the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock worth $77,069,000 after buying an additional 232,539 shares in the last quarter. Finally, Martin Capital Partners LLC boosted its position in Cencora by 205.2% in the 2nd quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock valued at $1,135,000 after buying an additional 2,544 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Trading Down 0.6%

NYSE:COR opened at $338.07 on Tuesday. The firm has a market capitalization of $65.58 billion, a P/E ratio of 42.52, a P/E/G ratio of 1.61 and a beta of 0.66. The business has a 50 day simple moving average of $349.47 and a 200 day simple moving average of $316.22. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. Cencora has a 12-month low of $223.92 and a 12-month high of $377.54.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same period last year, the company earned $3.34 earnings per share. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities research analysts predict that Cencora will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a dividend of $0.60 per share. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio (DPR) is presently 30.19%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.